Athira Pharma Inc ATHA.OQ ATHA.O is expected to report results on May 13 (estimated) for the period ending March 31 2025
LSEG's mean analyst estimate for Athira Pharma Inc is for a loss of 24 cents per share.
The current average analyst rating on the shares is "hold" and the breakdown of recommendations is no "strong buy" or "buy," 3 "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Athira Pharma Inc is $0.55, above its last closing price of $0.27.
This summary was machine generated May 9 at 11:59 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)